RESEARCH DIGEST — BREMELANOTIDE
PT-141 is the research designation for bremelanotide, a central melanocortin receptor agonist with one FDA-approved use.
A plain-spoken desktop of the record: how it works in the brain rather than the bloodstream, the single indication the approval covers, the honest tolerability profile, and the off-label evidence kept in its own window.
In plain English
PT-141 is another name for bremelanotide, a small lab-made peptide. A peptide is just a short chain of amino acids — the building blocks of proteins. PT-141 was approved by the US Food and Drug Administration (FDA) in 2019, but for exactly one thing: low sexual desire that causes real personal distress in premenopausal women, a condition called HSDD (hypoactive sexual desire disorder — persistent low sexual desire that the person finds genuinely distressing). It works on switches in the brain, not on blood flow. Every other use — in men, for erections, in older women — is off-label, meaning the approval does not cover it and the evidence is still early. This page lays out what is established and what is not.
What is PT-141 used for?
PT-141 (bremelanotide) has exactly one FDA-approved use: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [3]. The approval — New Drug Application 210557, granted June 21, 2019 — covers that population and that condition, and nothing else [6]. In the two pivotal Phase 3 trials, a 1.75 mg subcutaneous (injected just under the skin) dose taken as needed produced a statistically significant improvement in sexual desire and a reduction in the distress low desire caused [3].
Everything beyond that one indication is off-label. Use in men, use for erectile dysfunction, use in postmenopausal women, and use for general sexual "performance" are not part of the approval, and the evidence supporting them ranges from early-phase to preliminary [1]. This site keeps the approved use and the off-label record in separate windows on purpose — the difference is the whole story. For the off-label male evidence, see PT-141 for men; for the honest adverse-event picture, see PT-141 side effects.
PT-141 peptide: a synthetic melanocortin analogue
The PT-141 peptide is a synthetic cyclic heptapeptide — a ring of seven amino acids (sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) built to mimic alpha-MSH (alpha-melanocyte-stimulating hormone), a natural signaling molecule the body makes from a precursor protein called POMC [1]. Its molecular weight is 1025.2 Da and its formula is C50H68N14O10 [6]. The ring (a lactam bridge between two side chains) makes it sturdier than a straight-chain peptide, so it survives in the body longer than its linear relatives.
Structurally, PT-141 is a close relative of the older melanocortin peptide melanotan II, but with the tail end (the C-terminus) swapped from an amide to a carboxylic acid [1]. That small change shifts what the molecule does: rather than driving the skin-tanning and broad melanocortin effects of its cousin, PT-141 was developed specifically as a melanocortin receptor agonist (a molecule that switches melanocortin receptors on) for sexual desire [1]. "Bremelanotide" is simply the international nonproprietary name (INN) for the same molecule; the two names refer to one compound.
How PT-141 works: the brain, not the bloodstream
PT-141 works centrally — in the brain — by switching on melanocortin receptors, chiefly MC4R with secondary action at MC3R (melanocortin MC3R/MC4R receptors are brain switches that influence sexual desire, appetite and skin pigment) [1]. These receptors cluster in the hypothalamus and limbic system, the brain's motivation circuitry. By stimulating MC4R in regions such as the medial preoptic area, PT-141 is thought to engage dopamine pathways that govern sexual desire and arousal [1].
That central mechanism is the key fact about this compound, and it is what separates it from the more familiar erectile medications. PDE-5 inhibitors (a drug class, such as sildenafil, that improves erectile blood flow by acting on vessels) work peripherally, on vascular smooth muscle. PT-141 does not touch blood flow that way — it acts on the neural wiring of desire itself [1]. Direct evidence for the central mechanism came from a 2022 functional-MRI study: in premenopausal women with HSDD, MC4R agonism increased sexual desire for up to 24 hours and measurably altered how the brain processed erotic stimuli, including enhanced amygdala-insula connectivity [5]. For the full mechanism walk-through, open the RECONNECT clinical trials summary.
What is a melanocortin receptor agonist?
A melanocortin receptor agonist is a molecule that activates one or more of the five melanocortin receptors (MC1R through MC5R), a family of G-protein-coupled switches that respond to signals like alpha-MSH. PT-141 targets the central nervous-system subtypes, MC3R and MC4R [1]. MC4R is the principal target relevant to sexual desire; it also sits in appetite circuits, which is why high-frequency dosing in early metabolic research affected food intake — a pharmacological footnote, not an approved use [6]. Activation at the peripheral MC1R is the basis for the skin-darkening seen with repeated dosing [6].
Is PT-141 FDA-approved?
Yes — but only for one indication. The question "is PT-141 fda-approved" has a precise answer: bremelanotide injection was approved on June 21, 2019, under New Drug Application 210557, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [6]. That is the entire scope of the approval. Material sold online as a "PT-141 research chemical" is a different thing: it is intended for laboratory research, is not the approved finished drug product, and carries no regulatory oversight of its identity, purity, or concentration [6]. PT-141 is not a US controlled or scheduled substance; under anti-doping rules it falls within WADA's non-approved-substances framework, so athletes should consult current WADA guidance [3].